GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics

GT Biopharma announced that it had entered into a partnership agreement with Cytovance® Biologics Under the terms of the partnership agreement, Cytovance will be the exclusive GMP manufacture for three of the Company's TriKE™ therapeutic product candidates. Cytovance will manufacture TriKE™ in accordance with GMP using Cytovance's proprietary Keystone® bacterial or mammalian expression systems. Subject to the completion of certain milestones by Cytovance, GT Biopharma has the option to pay Cytovance up to $6 million for its manufacturing services in either cash or in shares of the Company's common stock valued at the time Cytovance achieves each of several milestones over the next 12 months.

Matt Delaney, MBA, M.I.B., Vice President Business Development & Marketing of Cytovance said "we are pleased to have been selected as GT Biopharma's exclusive GMP manufacturer for its first three TriKE™ product candidates." 

Mr. Delaney also stated "we believe our proprietary Keystone® bacterial or mammalian expression systems will deliver high production yields of TriKE™ further enhancing economies of scale."

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "We are pleased to have the opportunity to expand our partnership with Cytovance," 

Mr. Cataldo further stated. "The flexibility and breadth of our TriKE™ therapeutic platform allows us to quickly adapt to new disease targets, and rapidly advance TriKE™ product opportunities into the clinic."

SOURCE: GT Biopharma, Inc.

Related Posts

Subscribe Our Newsletter